Literature DB >> 11895951

Autocrine and exocrine regulation of interleukin-10 production in THP-1 cells stimulated with Borrelia burgdorferi lipoproteins.

Guillermo H Giambartolomei1, Vida A Dennis, Barbara L Lasater, P K Murthy, Mario T Philipp.   

Abstract

We have recently demonstrated that interleukin-10 (IL-10), produced by THP-1 monocytes in response to Borrelia burgdorferi lipoproteins, dampens the production of concomitantly elicited inflammatory cytokines. Thus, IL-10 could potentially down-regulate inflammatory and microbicidal effector mechanisms of the innate immune response to a B. burgdorferi infection, facilitating the establishment of the spirochete. To understand the mechanism(s) implicated in the regulation of the synthesis and release of IL-10 during early infection, we investigated the autocrine effects of IL-6, IL-12, tumor necrosis factor alpha (TNF-alpha), and IL-10 itself, as well as the exocrine effect of IFN-gamma on the production of macrophage-derived IL-10 with lipoprotein as a stimulant. In addition, in view of the differences in the receptor and signal transduction pathways of lipopolysaccharide (LPS) and bacterial lipoproteins, we also investigated the effects described above with LPS as a stimulant. The THP-1 human monocytic cell line and purified recombinant lipidated OspA (L-OspA) were used as the model target cell and stimulant, respectively. TNF-alpha increased the production of IL-10, as elicited by lipoproteins. The production of IL-10 by THP-1 cells stimulated with L-OspA was autoregulated by a negative feedback mechanism involving the IL-10 receptor (IL-10R). Exogenous IFN-gamma significantly inhibited the production of IL-10. Both autocrine (IL-10) and exocrine (IFN-gamma) inhibition of IL-10 production resulted in an increase in the production of the proinflammatory cytokines IL-6 and IL-12. The same results were obtained when the stimulant was LPS. The results further illustrate that IL-10 may play a pivotal role in Lyme disease pathogenesis. Moreover, the regulation of its production with lipoprotein as a stimulant is indistinguishable from that observed when LPS acts as a stimulant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895951      PMCID: PMC127882          DOI: 10.1128/IAI.70.4.1881-1888.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

1.  Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy.

Authors:  D H Libraty; L E Airan; K Uyemura; D Jullien; B Spellberg; T H Rea; R L Modlin
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

2.  Interferon-gamma enhances tumor necrosis factor-alpha production by inhibiting early phase interleukin-10 transcription.

Authors:  A N Shakhov; G Woerly; B D Car; B Ryffel
Journal:  Eur Cytokine Netw       Date:  1996-12       Impact factor: 2.737

3.  Inhibition of IL-10 expression by IFN-gamma up-regulates transcription of TNF-alpha in human monocytes.

Authors:  R P Donnelly; S L Freeman; M P Hayes
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

4.  Activation of human monocytic cells by Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides proceeds via a pathway distinct from that of lipopolysaccharide but involves the transcriptional activator NF-kappa B.

Authors:  M V Norgard; L L Arndt; D R Akins; L L Curetty; D A Harrich; J D Radolf
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

5.  T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines.

Authors:  Z Yin; J Braun; L Neure; P Wu; U Eggens; A Krause; T Kamradt; J Sieper
Journal:  Arthritis Rheum       Date:  1997-01

6.  Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytes/macrophages.

Authors:  J D Radolf; L L Arndt; D R Akins; L L Curetty; M E Levi; Y Shen; L S Davis; M V Norgard
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

7.  Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes.

Authors:  M P Hayes; J Wang; M A Norcross
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

8.  Enzymatically deacylated lipopolysaccharide (LPS) can antagonize LPS at multiple sites in the LPS recognition pathway.

Authors:  R L Kitchens; R S Munford
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

9.  Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.

Authors:  A M de Silva; S R Telford; L R Brunet; S W Barthold; E Fikrig
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

10.  The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells.

Authors:  X Ma; J M Chow; G Gri; G Carra; F Gerosa; S F Wolf; R Dzialo; G Trinchieri
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  18 in total

1.  Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae.

Authors:  Harald Gelderblom; Jens Schmidt; Diana Londoño; Yunhong Bai; Jacqueline Quandt; Ron Hornung; Adriana Marques; Roland Martin; Diego Cadavid
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  Lipoprotein-dependent and -independent immune responses to spirochetal infection.

Authors:  Juan C Salazar; Constance D Pope; Meagan W Moore; Jonathan Pope; Thomas G Kiely; Justin D Radolf
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

3.  Interleukin-10 anti-inflammatory response to Borrelia burgdorferi, the agent of Lyme disease: a possible role for suppressors of cytokine signaling 1 and 3.

Authors:  Vida A Dennis; Ayanna Jefferson; Shree R Singh; Frédéric Ganapamo; Mario T Philipp
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

4.  Influence of pathological progression on the balance between cellular and humoral immune responses in bovine tuberculosis.

Authors:  Michael D Welsh; Rodat T Cunningham; David M Corbett; R Martyn Girvin; James McNair; Robin A Skuce; David G Bryson; John M Pollock
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

5.  Immunochemical analysis of lipopolysaccharide-like component extracted from Borrelia burgdorferi sensu lato.

Authors:  K Schwarzová; I Ciznár
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

6.  Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice.

Authors:  Edwin Kanters; Manolis Pasparakis; Marion J J Gijbels; Monique N Vergouwe; Iris Partouns-Hendriks; Remond J A Fijneman; Björn E Clausen; Irmgard Förster; Mark M Kockx; Klaus Rajewsky; Georg Kraal; Marten H Hofker; Menno P J de Winther
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

7.  Differentiated THP-1 Cells Exposed to Pathogenic and Nonpathogenic Borrelia Species Demonstrate Minimal Differences in Production of Four Inflammatory Cytokines.

Authors:  John V Stokes; Gail M Moraru; Chelsea McIntosh; Evangel Kummari; Keiko Rausch; Andrea S Varela-Stokes
Journal:  Vector Borne Zoonotic Dis       Date:  2016-09-28       Impact factor: 2.133

8.  Borrelia burgdorferi-induced tolerance as a model of persistence via immunosuppression.

Authors:  Isabel Diterich; Carolin Rauter; Carsten J Kirschning; Thomas Hartung
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

9.  A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10.

Authors:  Jeong-Woo Kang; Seung-Chul Choi; Min-Chul Cho; Hee-Jong Kim; Jae-Hwa Kim; Jong-Seok Lim; Soo-Hyun Kim; Jae-Yong Han; Do-Young Yoon
Journal:  Immunology       Date:  2008-12-18       Impact factor: 7.397

10.  Microglia are mediators of Borrelia burgdorferi-induced apoptosis in SH-SY5Y neuronal cells.

Authors:  Tereance A Myers; Deepak Kaushal; Mario T Philipp
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.